Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gram Positive Infection Clear all
Completed Not applicable Interventional

An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)

NCT00002090
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Boston, Massachusetts • Syracuse, New York • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 5:00 PM EDT
Completed Phase 4 Interventional Results available

Mupirocin-Iodophor ICU Decolonization Swap Out Trial

NCT03140423
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Arm 1. Routine Care (Mupirocin/CHG), Arm 2. Iodophor/CHG Decolonization
Drug
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
Not listed
Enrollment
353,323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
137
States / cities
Riverside, California • San Jose, California • Thousand Oaks, California + 103 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Jul 22, 2026, 5:00 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI)

NCT01716533
View directory record Official record
Conditions
Infections, Clostridium Difficile
Interventions
Blood sampling, Stool sample collection
Procedure · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Little Rock, Arkansas • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Jul 22, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of MEDI4893

NCT02296320
View directory record Official record
Conditions
Staphylococcus Aureus Pneumonia
Interventions
MEDI4893, Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 130 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Jul 22, 2026, 5:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years

NCT02955160
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Tdap
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Jul 22, 2026, 5:00 PM EDT
Completed Phase 4 Interventional Results available

TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment

NCT03388268
View directory record Official record
Conditions
Clostridium Difficile Infection, Diarrhea
Interventions
Oral Vancomycin, Placebo, Toxin enzyme immunoassay, Nuceleic acid amplification test
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 25, 2021 · Synced Jul 22, 2026, 5:00 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Intrapartum Effect of Vancomycin on Rectovaginal GBS Colonization

NCT02814318
View directory record Official record
Conditions
Group B Streptococcal Infection
Interventions
Vaginal and rectovaginal swab cultures
Biological
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 5, 2020 · Synced Jul 22, 2026, 5:00 PM EDT
Completed No phase listed Observational

The Utility of Levofloxacin-Rifampin in the Therapy of Prosthetic Joint Infection

NCT00279864
View directory record Official record
Conditions
Staphylococcal Infection, Staphylococcus Aureus Prosthetic Joint Infection
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Jul 22, 2026, 5:00 PM EDT
Completed Not applicable Interventional Results available

Prevention of Recurrent Infections Caused by Community Acquired Staphylococcus Aureus (CA-SA) in Children

NCT00901316
View directory record Official record
Conditions
Community-Acquired Staphylococcus Aureus
Interventions
Routine Measures Group, Bleach Bath Group (Bleach plus routine measures)
Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Months to 18 Years
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Jul 22, 2026, 5:00 PM EDT
Completed Phase 3 Interventional

TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis

NCT00023335
View directory record Official record
Conditions
Pulmonary Tuberculosis
Interventions
Rifapentine, Isoniazid
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2005 · Synced Jul 22, 2026, 5:00 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

MSSA and MRSA Screening in Patients Undergoing Elective TJA: the Benefits of Next-generation Sequencing

NCT04574752
View directory record Official record
Conditions
Staphylococcus Aureus, Next Generation Sequencing, Total Joint Arthroplasty
Interventions
next generation sequencing
Diagnostic Test
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years to 80 Years
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Jul 22, 2026, 5:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults

NCT01574638
View directory record Official record
Conditions
Tuberculosis
Interventions
Rifapentine (RPT)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
San Diego, California • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Jul 22, 2026, 5:00 PM EDT
Withdrawn Phase 4 Interventional

Addition of Lactobacillus to Metronidazole in Treatment of CDAD

NCT00304863
View directory record Official record
Conditions
Enterocolitis, Pseudomembranous Colitis, Antibiotic-associated Colitis
Interventions
Lactobacillus GG
Drug
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Jul 22, 2026, 5:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

NCT03758612
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
TBI-223 oral suspension, TBI-223 enteric capsule, TBI-223 SR Tablet Prototype 1, TBI-223 SR Tablet Prototype 2, TBI-223 SR Tablet Prototype 3, TBI-223 IR Tablet, Placebo suspension
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Jul 22, 2026, 5:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

NCT05489328
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
Candidate-1, Candidate-2, Candidate-3, Candidate-4, Candidate-5, Candidate-6, Candidate Control, 13vPnC, PCV15
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
18
States / cities
Tustin, California • Walnut Creek, California • Milford, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Jul 22, 2026, 5:00 PM EDT
Terminated No phase listed Observational

CD8 Reactivity to Microorganisms in Blood and Breast Milk

NCT03084614
View directory record Official record
Conditions
Immune Modulation, Tuberculosis, Leprosy, Pertussis, Lyme Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Jul 22, 2026, 5:00 PM EDT
Not yet recruiting Early Phase 1 Interventional

Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy

NCT06884748
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Ursodiol 500 MG
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 22, 2026, 5:00 PM EDT
Withdrawn Not applicable Interventional

Treatment of C. Difficile Infection With Fecal Microbiota Transplantation (FMT)

NCT01842347
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Fecal microbiota
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Jul 22, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea

NCT01925417
View directory record Official record
Conditions
Recurrent Clostridium Difficile Infection
Interventions
RBX2660 (microbiota suspension)
Biological
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Jul 22, 2026, 5:00 PM EDT
Completed No phase listed Observational

Rapid Test to Detect Staphylococcus Aureus in Blood and Wound Infections

NCT01198262
View directory record Official record
Conditions
Staphylococcus Aureus, Staphylococcal Skin Infections, Bacteremia
Interventions
Not listed
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2010 · Synced Jul 22, 2026, 5:00 PM EDT
Recruiting Not applicable Interventional

Economic Incentives and vDOT for Latent Tuberculosis Infection

NCT05022862
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
Usual Care, Video Directly Observed Therapy alone, Video Directly Observed Therapy plus Financial Incentives
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 22, 2026, 5:00 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines

NCT00148941
View directory record Official record
Conditions
Tetanus, Acellular Pertussis, Diphtheria
Interventions
SB213503 lot 1, SB213503 lot 2, SB213503 lot 3, Infanrix, IPOL, M-M-R II
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 6 Years
Enrollment
4,209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
24
States / cities
Little Rock, Arkansas • Antioch, California • Daly City, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jul 22, 2026, 5:00 PM EDT
Not listed Phase 4 Interventional

Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe

NCT01630096
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
Nu-Lytely
Drug
Lead sponsor
Ascension Health
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Grand Blanc, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Jul 22, 2026, 5:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care

NCT05226260
View directory record Official record
Conditions
Cellulitis, Abscess, Drain Abscess, Impetigo, Skin Infection, Antibiotic Duration, Behavioral Economics
Interventions
Default Duration order Panel
Behavioral
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
3 Months to 99 Years
Enrollment
1,634 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Jul 22, 2026, 5:00 PM EDT